

**Beneficiary Advisory Panel Handout  
Uniform Formulary Decisions  
08 Jan 2009**

**PURPOSE:** The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

**Table 1: Uniform Formulary Recommendations from the November 2008  
DoD P&T Committee Meeting**

| UF Status / Implementation Period         | Generic Name (Brand)                                    | Formulations         | Generics Available? |
|---|---|----------------------|---------------------|
| <b>Nasal Allergy Drugs</b>                |   |                      |                     |
| <b>Formulary</b>                          | Azelastine (Astelin)                                    | nasal inhaler        | No                  |
|   | Flunisolide (Nasarel, generics)                         | nasal inhaler        | Yes                 |
|   | Fluticasone propionate (Flonase, generics)              | nasal inhaler        | Yes                 |
|   | Mometasone (Nasonex)                                    | nasal inhaler        | No                  |
|   | Ipratropium (Atrovent)                                  | nasal inhaler        | Yes                 |
| <b>Non-Formulary</b>                      | Beclomethasone (Beconase AQ)                            | nasal inhaler        | No                  |
|   | Budesonide (Rhinocort Aqua)                             | nasal inhaler        | No                  |
|   | Ciclesonide (Omnaris)                                   | nasal inhaler        | No                  |
|   | Fluticasone furoate (Veramyst)                          | nasal inhaler        | No                  |
|   | Triamcinolone (Nasacort AQ)                             | nasal inhaler        | No                  |
|   | Olopatadine (Patanase)                                  | nasal inhaler        | No                  |
| <b>Recommended implementation period</b>  | 60 days   |                      |                     |
| <b>Short-Acting Beta Agonists (SABAs)</b> |   |                      |                     |
| <b>Formulary</b>                          | Albuterol solution (Accuneb, generics)                  | inhalation solution  | Yes                 |
|   | Levalbuterol solution (Xopenex)                         | inhalation solution  | No                  |
|   | Albuterol inhaler (Proair, Proventil HFA, Ventolin HFA) | metered dose inhaler | No                  |
|   | Levalbuterol inhaler (Xopenex)                          | metered dose inhaler | No                  |
| <b>Non-Formulary*</b>                     | Metaproterenol solution (Alupent, generics)             | inhalation solution  | Yes                 |
|   | Pirbuterol inhaler (Maxair)                             | metered dose inhaler | No                  |
| <b>Recommended implementation period</b>  | 60 days   |                      |                     |

\*: Note regarding non-formulary SABAs: Generic formulations of albuterol metered dose inhaler and metaproterenol metered dose inhaler (Alupent) will no longer be marketed after 31 Dec 2008, due to ban of chlorofluorocarbon propellant

Figure 1: Nasal Allergy Drugs

# Nasal Allergy Drug Utilization

MHS Utilization of Nasal Allergy Drugs




Figure 2: Nasal Allergy Drugs

## Nasal Allergy Drug Utilization MHS without Flonase




Figure 3: Short-Acting Beta Agonists – Metered Dose Inhaler





Figure 4: Short-Acting Beta Agonists – Inhalation Solution



**Table 6: Uniform Formulary Implementation Plan Summary**

| Meeting | Drug Class                                       | Non-Formulary Medications   | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |        |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification  | Step Therapy |
|---------|--|---|---|-------------------------------|--------|------------|---|--|--------------|
|         |  |   |   | MTF                           | Retail | Mail Order |   |  |              |
| Nov 08  | Inhaled Short Acting Beta Agonist                | <ul style="list-style-type: none"> <li>▪ Metaproterenol inhaled solution</li> <li>▪ Pirbuterol CFC MDI (Maxair)</li> </ul>  | 1,278   | 44                            | 1,002  | 232        | 60  | Small number of beneficiaries affected   | No           |
| Nov 08  | Nasal Allergy Drugs                              | <ul style="list-style-type: none"> <li>▪ Beclomethasone (Beconase AQ)</li> <li>▪ Budesonide (Rhinocort AQ)</li> <li>▪ Ciclesonide (Omnaris)</li> <li>▪ Fluticasone Furoate (Veramyst)</li> <li>▪ Triamcinolone (Nasacort AQ)</li> <li>▪ Olopatadine (Patanase)</li> </ul>   | 34,271  | 440                           | 27,017 | 6,814      | 60  | Nasal corticosteroids reviewed Nov 05, no changes to UF other than Patanase and Omnaris made non-formulary (1,794 users) | No           |
| Aug 08  | Self-Monitoring Blood Glucose System Test Strips | <ul style="list-style-type: none"> <li>▪ One Touch (for One Touch Ultra 2, Ultra Mini, and Ultra Smart meters)</li> <li>▪ TrueTrack strips (for TrueTrack meter)</li> <li>▪ Accu-chek Comfort Curve strips (for Accu-chek Advantage meter)</li> <li>▪ Accu-chek Compact Plus drum (for Accu-check Compact Plus meter)</li> <li>▪ Accu-chek Simplicity, Ascensia Autodisk, Ascensia Breeze 2, Ascensia Elite, Assure, Assure 3, Assure II, Assure Pro, Bd Test Strips, Chemstrip Bg, Control AST, Dextrostix Reagent, Easygluco, Easypro, Fast Take, Freestyle test strips (other than Freestyle Lite), Glucofilm, Glucolab, Glucometer Dex, Glucometer Elite, Glucose Test Strip, Glucostix, Optium, Precision Pcx, Precision Pcx Plus, Precision Q-I-D, Precision Sof-Tact, Prestige Smart System, Prodigy, Quicktek, Sidekick, Sof-Tact, Surestep, Surestep Pro, Test Strip,</li> </ul> | 58,142  | 12,271                        | 33,658 | 12,231     | 120   | Allow time for patients to receive new meters  | No           |

| Meeting | Drug Class               | Non-Formulary Medications   | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |        |                                      | Implementation Plan<br>First Wednesday X days after the decision date | Justification                                       | Step Therapy |
|---------|--------------------------|---|---|-------------------------------|--------|--------------------------------------|---|---|--------------|
|         |                          |   |   | MTF                           | Retail | Mail Order                           |   |   |              |
|         |                          | <ul style="list-style-type: none"> <li>Relion Ultima, Uni-Check</li> <li>Plus all other store/private label brand strips not included on Uniform Formulary (see the BCF/ECF column)</li> </ul>  |   |                               |        |                                      |   |   |              |
| Aug 08  | Overactive Bladder Drugs | <ul style="list-style-type: none"> <li>Tolterodine IR (Detrol)</li> <li>Trospium IR (Sanctura)</li> </ul>   | 4,215   | 235                           | 1,210  | 2,770                                | 90  | Typical 90-day implementation period                | No           |
| Aug 08  | Antidepressant – 1s      | <ul style="list-style-type: none"> <li>Desvenlafaxine (Pristiq)</li> </ul>  | 745   | 0                             | 694    | 51                                   | 60  | New drug in already reviewed class; low utilization | No           |
|         |                          | <i>Original Meeting Nov 05</i> <ul style="list-style-type: none"> <li>paroxetine HCl CR (Paxil)</li> <li>fluoxetine 90 mg for weekly administration (Prozac Weekly)</li> <li>fluoxetine in special packaging for PMDD (Sarafem)</li> <li>escitalopram (Lexapro)</li> <li>duloxetine (Cymbalta)</li> <li>bupropion extended release (Wellbutrin XL)</li> </ul> | See previous meetings below in table                  |                               |        | See previous meetings below in table | See previous meetings below in table                                  | No  |              |
| Aug 08  | Calcium Channel Blockers | <ul style="list-style-type: none"> <li>Nisoldipine geomatrix (Sular geomatrix)</li> </ul>   | 2,027   | 56                            | 1,188  | 783                                  | 60  | New drug in already reviewed class; low utilization | No           |
|         |                          | <i>Original Meeting Aug 05</i> <ul style="list-style-type: none"> <li>amlodipine (Norvasc) <ul style="list-style-type: none"> <li>Nov 07: removed from NF status</li> </ul> </li> <li>isradipine IR (Dynacirc)</li> <li>isradipine ER (Dynacirc CR)</li> </ul>  | See previous meetings below in table                  |                               |        | See previous meetings below in table | See previous meetings below in table                                  | No  |              |



| Meeting | Drug Class  | Non-Formulary Medications   | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |        |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification                                       | Step Therapy |
|---------|---|---|---|-------------------------------|--------|------------|---|---|--------------|
|         |   |   |   | MTF                           | Retail | Mail Order |   |   |              |
|         |   | <ul style="list-style-type: none"> <li>nicardipine IR (Cardene, generics)</li> <li>nicardipine SR (Cardene SR)</li> <li>verapamil ER (Verelan)</li> <li>verapamil ER for bedtime dosing (Verelan PM, Covera HS)</li> <li>diltiazem ER for bedtime dosing (Cardizem LA)</li> </ul> |   |                               |        |            |   |   |              |
| Jun 08  | Triptans  | <ul style="list-style-type: none"> <li>Almotriptan (Axert)</li> <li>Frovatriptan (Frova)</li> <li>Naratriptan (Amerge)</li> </ul>   | 3,763   | 208                           | 3,212  | 343        | (26 Nov 2008)<br>90 days  | Typical 90-day implementation period                | No           |
| Jun 08  | Osteoporosis Agents   | <ul style="list-style-type: none"> <li>Salmon-calcitonin (Miacalcin)</li> </ul>   | 2,914   | 945                           | 1,948  | 1,021      | (26 Nov 2008)<br>90 days  | Typical 90-day implementation period                | No           |
| Jun 08  | Newer Antihistamines (NAs) (new drug in previously reviewed class);<br>Original decision Aug 07 | <ul style="list-style-type: none"> <li>Levocetirizine (Xyzal)</li> </ul>  | 19,254  | 0                             | 19,254 | 0          | (29 Oct 2008)<br>60 days  | New drug in already reviewed class                  | No           |
|         |   | <i>Original Meeting Aug 07</i> <ul style="list-style-type: none"> <li>desloratadine (Clarinet)</li> <li>desloratadine/pseudoephed. (Clarinet D)</li> </ul>  | 27,396  | 60                            | 20,102 | 7,234      | See previous meetings below in table                                  | Typical 90-day implementation period                | No           |
| Jun 08  | Leukotriene Modifiers (LMs (new drug in previously reviewed class);<br>Original decision Aug 07 | <ul style="list-style-type: none"> <li>Zileuton extended release (Zyflo CR)</li> </ul>  | 288   | 0                             | 288    | 0          | (29 Oct 2008)<br>60 days  | New drug in already reviewed class; low utilization | No           |
|         |   | <i>Original Meeting Aug 07</i> <ul style="list-style-type: none"> <li>zileuton (Zyflo)</li> </ul>   | 144   | 4                             | 110    | 31         | See previous meetings below in table                                  | Typical 90-day implementation period                | No           |

| Meeting | Drug Class  | Non-Formulary Medications  | Total Beneficiaries Affected (# of patients affected)              | Beneficiaries Affected by POS |        |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification   | Step Therapy |
|---------|---|--|--|-------------------------------|--------|------------|---|---|--------------|
|         |   |  |  | MTF                           | Retail | Mail Order |   |   |              |
| Jun 08  | Beta Adrenergic Receptor Blockers (ABAs) (new drug in previously reviewed class);<br>Original decision Nov 07 | <ul style="list-style-type: none"> <li>▪ Nebivolol (Bystolic)</li> </ul>   | 2,462  | 0                             | 2,462  | 0          | (29 Oct 2008)<br>60 days  | New drug in already reviewed class; low utilization             | No           |
|         |   | Original Meeting Nov 07<br>(No drugs designated non formulary)   | 0  | 0                             | 0      | 0          | See previous meetings below in table                                  | No meds moved to non-formulary status                           | No           |
| Jun 08  | Renin Antihypertensive Agents (RAAs) (new drug in previously reviewed class);                                 | ARB/CCB combos (Jun 08)<br><ul style="list-style-type: none"> <li>▪ Olmesartan / amlodipine (Azor)</li> </ul>  | 2,641  | 0                             | 2,641  | 0          | (29 Oct 2008)<br>60 days  | New drug in already reviewed class with current low utilization | No           |
|         |   | ARB/CCB combos (Nov 07)<br><ul style="list-style-type: none"> <li>▪ valsartan / amlodipine (Exforge)</li> </ul>  | 2,376  | 0                             | 2,376  | 0          | (16 Apr 2008)<br>60 days  | New drug in already reviewed class with current low utilization | No           |
|         |   | ARBs – (May 07 meeting)<br><ul style="list-style-type: none"> <li>▪ eprosartan (Teveten)</li> <li>▪ eprosartan HCTZ (Teveten HCT)</li> <li>▪ irbesartan (Avapro)</li> <li>▪ irbesartan HCTZ (Avalide)</li> <li>▪ olmesartan (Benicar)</li> <li>▪ olmesartan HCTZ (Benicar HCT)</li> <li>▪ valsartan (Diovan)</li> <li>▪ valsartan HCTZ (Diovan HCT)</li> </ul> ACE/CCB combos – Feb 06 meeting<br><ul style="list-style-type: none"> <li>▪ felodipine/enalapril (Lexxel)</li> <li>▪ verapamil/trandolapril (Tarka)</li> </ul> ACE Inhibitors (Aug 05 meeting)<br><ul style="list-style-type: none"> <li>▪ moexipril (Univasc),</li> <li>▪ moexipril / HCTZ (Uniretic)</li> <li>▪ perindopril (Aceon)</li> <li>▪ quinapril (Accupril)</li> <li>▪ quinapril / HCTZ (Accuretic)</li> <li>▪ ramipril (Altace)</li> </ul> | See previous meetings for affected beneficiaries for each subclass |                               |        |            | See previous meetings below in table                                  | See previous meetings below in table                            |              |

| Meeting | Drug Class   | Non-Formulary Medications  | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |           |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification   | Step Therapy |
|---------|--|--|---|-------------------------------|-----------|------------|---|---|--------------|
|         |  |  |   | MTF                           | Retail    | Mail Order |   |   |              |
| Nov 07  | Benign Prostatic Hypertension (BPH)<br>Alpha Blockers (ABs)  | <ul style="list-style-type: none"> <li>tamsulosin (Flomax)</li> </ul>  | 64,783  | 1,426                         | 40,161    | 23,196     | (16 Apr 2008)<br>60-days  | 3 <sup>rd</sup> class for Step Therapy  | Yes          |
| Nov 07  | Targeted Immunomodulatory Biologics (TIBs)   | <ul style="list-style-type: none"> <li>etanercept (Enbrel)</li> <li>anakinra (Kineret)</li> </ul>  | 7,397   | 1,939                         | 4,149     | 1,309      | (18 Jun 2008)<br>90-days  | Typical 90-day implementation period  | No           |
| Nov 07  | Attention Deficit Hyperactivity Disorder (ADHD) / Narcolepsy agents (new drug in previously reviewed class);<br>Previous decision Nov 06 | <ul style="list-style-type: none"> <li>lisdexamfetamine (Vyvanse)</li> </ul>   | 2,200 Rxs   | 0                             | 2,200 Rxs | 0          | (16 Apr 2008)<br>60 days  | New drug in already reviewed class with current low utilization                         | No           |
|         |  | <i>Original decision Nov 06</i> <ul style="list-style-type: none"> <li>Dexmethylphenidate IR (Focalin)</li> <li>Dexmethylphenidate SODAS (Focalin XR)</li> <li>Methylphenidate transdermal patch (Daytrana)</li> </ul>                   | 3,078 (1.7% of patients receiving an ADHD drug)       | 62                            | 2,965     | 51         | 18 Apr 07<br>(90 days)  | Small number of beneficiaries affected  |              |
| Nov 07  | Contraceptive Agents (new drug in previously reviewed class);<br>Previous decisions May 06, Nov 06                                       | <ul style="list-style-type: none"> <li>EE 20 mcg / levonorgestrel 0.09 mg (Lybrel)</li> </ul>  | 290 Rxs   | 2 Rxs                         | 263 Rxs   | 25 Rxs     | (16 Apr 2008)<br>60 days  | New drug in already reviewed class with current low utilization                         | No           |
|         |  | <i>Previous meetings May 06 &amp; Nov 06</i> <ul style="list-style-type: none"> <li>EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale)</li> <li>EE 25 mcg / norethindrone 0.4 mg (Ovcon 35)</li> </ul> | 23,221 (4% of patients receiving a contraceptive)     | 3,128                         | 19,249    | 844        | 24 Jan 07<br>(180 days)   | Seasonale, packaged as a 3-month supply; Loestrin 24 FE and Seasonique to coincide with |              |

| Meeting | Drug Class  | Non-Formulary Medications   | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |           |            | Implementation Plan<br>First Wednesday X days after the decision date  | Justification   | Step Therapy |
|---------|---|---|---|-------------------------------|-----------|------------|--|---|--------------|
|         |   |   |   | MTF                           | Retail    | Mail Order |  |   |              |
|         |   | <ul style="list-style-type: none"> <li>EE 50 mcg / norethindrone 1 mg (Ovcon 50)</li> <li>EE 20/30/35 mcg / norethindrone 1 mg (Estrostep Fe)</li> <li>EE 20 mcg/1 mg norethindrone- 24 day regimen (Loestrin 24 Fe)</li> <li>EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique)</li> </ul> | Seasonique: 161<br>(from Apr 06-Oct 06)               | 0 Rxs                         | 112 Rxs   | 4 Rxs      |  | Seasonale decision  |              |
|         |   |   | Loestrin 24 Fe:<br>2,227<br>(from Apr 06-Oct 06)      | 22 Rxs                        | 3,417 Rxs | 64 Rxs     |  |   |              |
| Aug 07  | Nasal Corticosteroid Agents<br>(new drug in previously reviewed class);<br>Original decision Nov 05 | <ul style="list-style-type: none"> <li>fluticasone furoate (Veramyst)</li> </ul>  | 650   | 0                             | 650       | 0          | TMOP & TRRx: 60-days for current users;<br>\$22 co-pay in effect immediately for new users<br>MTF: No later than 60 days | New drug in already reviewed class with current low utilization | No           |
|         |   | <i>Original Decision: Nov 05</i> <ul style="list-style-type: none"> <li>beclomethasone dipropionate (Beconase AQ, Vancenase AQ)</li> <li>budesonide (Rhinocort Aqua)</li> <li>triamcinolone (Nasacort AQ)</li> </ul>  |   |                               |           |            | 19 Jan 06<br>(90 days)   | Substantial number of beneficiaries                             |              |
| Aug 07  | Growth Stimulating Agents (GSAs)  | <ul style="list-style-type: none"> <li>somatropin (Genotropin, Genotropin Miniquick)</li> <li>somatropin (Humatrope)</li> <li>somatropin (Omnitrope)</li> <li>somatropin (Saizen)</li> </ul>  | 653   | 77                            | 310       | 266        | TMOP & TRRx: 60-days for current users;<br>MTF: No later than 60 days  | Low number of affected beneficiaries affected                   | No           |
| May 07  | Antilipidemic II Agents (LIP-2s)  | <ul style="list-style-type: none"> <li>fenofibrate nanocrystallized (Tricor)</li> <li>fenofibrate micronized (Antara)</li> <li>omega-3 fatty acids (Omacor)</li> <li>colesevelam (Welchol)</li> </ul>   | 83,612  | 18,849                        | 44,402    | 20,361     | 24 Oct 07<br>(90 days)   | Typical 90-day implementation period                            | No           |
| May 07  | 5-Alpha Reductase Inhibitors (5-ARIs)   | <ul style="list-style-type: none"> <li>dutasteride (Avodart)</li> </ul>   | 20,917  | 1,087                         | 12,830    | 7,000      | 24 Oct 07<br>(90 days)   | Typical 90-day implementation period                            | No           |

| Meeting                        | Drug Class               | Non-Formulary Medications   | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |         |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification   | Step Therapy |
|--------------------------------|--------------------------|---|---|-------------------------------|---------|------------|---|---|--------------|
|                                |                          |   |   | MTF                           | Retail  | Mail Order |   |   |              |
| May 07<br>(Update from Feb 05) | PPIs                     | <ul style="list-style-type: none"> <li>▪ lansoprazole (Prevacid)</li> <li>▪ omeprazole/sodium bicarbonate (Zegerid)</li> <li>▪ pantoprazole (Protonix)</li> <li>▪ rabeprazole (Aciphex)</li> </ul>  | 453,525   | 212,130                       | 178,120 | 63,275     | 24 Oct 07<br>(90 days)  | Typical 90-day implementation period                        | Yes          |
| May 07<br>(Update from Feb 05) | ARBs                     | <ul style="list-style-type: none"> <li>▪ eprosartan (Teveten)</li> <li>▪ eprosartan HCTZ (Teveten HCT)</li> <li>▪ irbesartan (Avapro)</li> <li>▪ irbesartan HCTZ (Avalide)</li> <li>▪ olmesartan (Benicar)</li> <li>▪ olmesartan HCTZ (Benicar HCT)</li> <li>▪ valsartan (Diovan)</li> <li>▪ valsartan HCTZ (Diovan HCT)</li> </ul> | 228,581   | 68,059                        | 109,595 | 50,930     | 21 Nov 07<br>(120 days)   | Reservations regarding ESI ability to handle implementation | No           |
| Feb 07                         | Newer Sedative Hypnotics | <ul style="list-style-type: none"> <li>▪ Ramelteon (Rozerem)</li> <li>▪ Zaleplon (Sonata)</li> <li>▪ Zolpidem ER (Ambien CR)</li> </ul>   | 40,447  | 5,878                         | 31,550  | 3,019      | 1 Aug 07<br>(90 days)   | First time automated PA with step edit                      | Yes          |
| Feb 07                         | Narcotic Analgesics      | <ul style="list-style-type: none"> <li>▪ Tramadol ER (Ultram ER)</li> </ul>   | 1,088   | 0                             | 46      | 1,042      | 1 Aug 07<br>(90 days)   | Small number of beneficiaries affected                      | No           |
| Feb 07                         | Glaucoma Agents          | <ul style="list-style-type: none"> <li>▪ Travoprost (Travatan, Travatan Z)</li> <li>▪ Timolol maleate (Istalol)</li> <li>▪ Timolol hemihydrate (Betimol)</li> <li>▪ Brinzolamide (Azopt)</li> </ul>   | 17,139  | 1,735                         | 12,267  | 3,117      | 1 Aug 07<br>(90 days)   | Small number of beneficiaries affected                      | No           |
| Feb 07                         | MAOI Antidepressants     | <ul style="list-style-type: none"> <li>▪ Selegiline transdermal system (Emsam)</li> </ul>   | 168   | 0                             | 157     | 11         | 1 Aug 07<br>(90 days)   | Small number of beneficiaries affected                      | No           |
| Nov 06                         | ADHD                     | <ul style="list-style-type: none"> <li>▪ Dexmethylphenidate IR (Focalin)</li> <li>▪ Dexmethylphenidate SODAS (Focalin XR)</li> <li>▪ Methylphenidate transdermal patch (Daytrana)</li> </ul>  | 3,078 (1.7% of patients receiving an ADHD drug)       | 62                            | 2,965   | 51         | 18 Apr 07<br>(90 days)  | Small number of beneficiaries affected                      | No           |
| Nov 06                         | Older Sedative Hypnotics | -   | 0   | 0                             | 0       | 0          | 18 Apr 07<br>(90 days)  | No medications moved to non-formulary status                | No           |
| Aug 06                         | TZDs                     | -   | 0   | 0                             | 0       | 0          | Not applicable  | No medications moved to non-formulary status                | No           |

| Meeting                               | Drug Class                      | Non-Formulary Medications   | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |           |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification   | Step Therapy |
|---------------------------------------|---------------------------------|---|---|-------------------------------|-----------|------------|---|---|--------------|
|                                       |                                 |   |   | MTF                           | Retail    | Mail Order |   |   |              |
| Aug 06                                | H2 Antagonists / GI protectants | -   | 0   | 0                             | 0         | 0          | Not applicable  | No medications moved to non-formulary status  | No           |
| Aug 06                                | Antilipidemic I Agents          | <ul style="list-style-type: none"> <li>Rosuvastatin (Crestor)</li> <li>Atorvastatin / amlodipine (Caduet)</li> </ul>  | 44,078  | 851                           | 36,133    | 6,921      | 1 Feb 07 (90 days)  | Small number of beneficiaries affected  | No           |
| May 06                                | Antiemetics                     | <ul style="list-style-type: none"> <li>Dolasetron (Anzemet)</li> </ul>  | 852   | 14                            | 668       | 170        | 27 Sept 06 (60 days)  | Small number of beneficiaries affected, and acute nature of treatment (e.g., chemotherapy)  | No           |
| May 06 update for new drugs<br>Nov 06 | Contraceptive Agents            | <i>Original Decision May 06</i> <ul style="list-style-type: none"> <li>EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale)</li> <li>EE 25 mcg / norethindrone 0.4 mg (Ovcon 35)</li> <li>EE 50 mcg / norethindrone 1 mg (Ovcon 50)</li> <li>EE 20/30/35 mcg / norethindrone 1 mg (Estrostep Fe)</li> </ul> | 23,221 (4% of patients receiving a contraceptive)     | 3,128                         | 19,249    | 844        | 24 Jan 07 (180 days)  | Relatively low number of beneficiaries affected, but a high proportion are receiving Seasonale, which is packaged as a 3-month supply | No           |
|                                       |                                 | <i>Nov 06</i> <ul style="list-style-type: none"> <li>EE 20 mcg/1 mg norethindrone- 24 day regimen (Loestrin 24 Fe)</li> <li>EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique)</li> </ul>   | Seasonique 161 (from Apr 06-Oct 06)                   | 0 Rxs                         | 112 Rxs   | 4 Rxs      | Jan 24 07 (60 days; to coincide with Seasonal)                        | Small number of beneficiaries affected  | No           |
|                                       |                                 |   | Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)            | 22 Rxs                        | 3,417 Rxs | 64 Rxs     |   |   |              |

| Meeting | Drug Class                     | Non-Formulary Medications  | Total Beneficiaries Affected (# of patients affected)                     | Beneficiaries Affected by POS |         |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification  | Step Therapy |
|---------|--------------------------------|--|---|-------------------------------|---------|------------|---|--|--------------|
|         |                                |  |   | MTF                           | Retail  | Mail Order |   |  |              |
| Feb 06  | OABs                           | <ul style="list-style-type: none"> <li>▪ tolterodine IR (Detrol)</li> <li>▪ oxybutynin patch (Oxytrol)</li> <li>▪ trospium (Sanctura)</li> </ul>   | 19,118  | 2,596                         | 13,471  | 3,051      | 26 July 06<br>(90 days)   | Recommended 60-day implementation overturned; 90-day BAP recommendation accepted   | No           |
| Feb 06  | Misc Anti-hypertensive Agents  | <ul style="list-style-type: none"> <li>▪ felodipine/enalapril (Lexxel)</li> <li>▪ verapamil/trandolapril (Tarka)</li> </ul>  | 5,946   | 336                           | 4,472   | 1,138      | 26 July 06<br>(90 days)   | Recommended 60-day implementation overturned; 90-day BAP recommendation accepted   | No           |
| Feb 06  | GABA-analogs                   | <ul style="list-style-type: none"> <li>▪ pregabalin (Lyrica)</li> </ul>  | 30,649  | 1,120                         | 27,566  | 1,963      | 28 Jun 06<br>(60 days)  | Small number of beneficiaries affected   | No           |
| Nov 05  | Alzheimer's Drugs              | <ul style="list-style-type: none"> <li>▪ tacrine (Cognex)</li> </ul>   | 5   | 0                             | 3       | 2          | 19 Apr 06<br>(90 days)  | Small number of beneficiaries affected   | No           |
| Nov 05  | Nasal Corticosteroid Agents    | <ul style="list-style-type: none"> <li>▪ beclomethasone dipropionate (Beconase AQ, Vancenase AQ)</li> <li>▪ budesonide (Rhinocort Aqua)</li> <li>▪ triamcinolone (Nasacort AQ)</li> </ul>  | 96,999  | 13,556                        | 73,381  | 10,062     | 19 Apr 06<br>(90 days)  | Substantial number of beneficiaries affected   | No           |
| Nov 05  | Macrolide/Ketolide Antibiotics | <ul style="list-style-type: none"> <li>▪ azithromycin 2 gm (Zmax)</li> <li>▪ telithromycin (Ketek)</li> </ul>  | Total number not provided; antibiotics are used to treat acute infections |                               |         |            | 22 Mar 06<br>(60 days)  | Small number of beneficiaries affected, Medication used to treat acute (not chronic) infections not likely to require therapy change | No           |
| Nov 05  | Antidepressants I              | <ul style="list-style-type: none"> <li>▪ paroxetine HCl CR (Paxil)</li> <li>▪ fluoxetine 90 mg for weekly administration (Prozac Weekly)</li> <li>▪ fluoxetine in special packaging for PMDD (Sarafem)</li> <li>▪ escitalopram (Lexapro)</li> <li>▪ duloxetine (Cymbalta)</li> <li>▪ bupropion extended release (Wellbutrin XL)</li> </ul> | 182,916   | 52,624                        | 118,582 | 11,710     | 19 Jul 06<br>(180 days)   | Substantial number of beneficiaries affected   | No           |

| Meeting                            | Drug Class   | Non-Formulary Medications   | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |         |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification  | Step Therapy |
|------------------------------------|--|---|---|-------------------------------|---------|------------|---|--|--------------|
|                                    |  |   |   | MTF                           | Retail  | Mail Order |   |  |              |
| Aug 05                             | Alpha Blockers for BPH                             | <ul style="list-style-type: none"> <li>▪ tamsulosin (Flomax)</li> </ul>   | 89,926  | 26,692                        | 47,674  | 15,560     | 15 Feb 06 (120 days)  | Substantial number of beneficiaries affected   | No           |
| Aug 05                             | CCBs   | <ul style="list-style-type: none"> <li>▪ amlodipine (Norvasc) <ul style="list-style-type: none"> <li>○ Nov 07: amlodipine removed from NF status</li> </ul> </li> <li>▪ isradipine IR (Dynacirc)</li> <li>▪ isradipine ER (Dynacirc CR)</li> <li>▪ nicardipine IR (Cardene, generics)</li> <li>▪ nicardipine SR (Cardene SR)</li> <li>▪ verapamil ER (Verelan)</li> <li>▪ verapamil ER for bedtime dosing (Verelan PM, Covera HS)</li> <li>▪ diltiazem ER for bedtime dosing (Cardizem LA)</li> </ul> | 274,616   | 133,794                       | 101,345 | 39,477     | 15 Mar 06 (150 days)  | Substantial number of beneficiaries affected   | No           |
| Aug 05                             | ACE Inhibitors & ACE Inhibitor / HCTZ Combinations | <ul style="list-style-type: none"> <li>▪ moexipril (Univasc),</li> <li>▪ moexipril / HCTZ (Uniretic)</li> <li>▪ perindopril (Aceon)</li> <li>▪ quinapril (Accupril)</li> <li>▪ quinapril / HCTZ (Accuretic)</li> <li>▪ ramipril (Altace)</li> </ul>   | 158,101   | 77,159                        | 57,982  | 22,959     | 16 Feb 06 (120 days)  | Substantial number of beneficiaries affected   | No           |
| May 05                             | PDE-5 Inhibitors                                   | <ul style="list-style-type: none"> <li>▪ sildenafil (Viagra)</li> <li>▪ tadalafil (Cialis)</li> </ul>   | 128,007   | 55,161                        | 49,850  | 22,996     | 12 Oct 05 (90 days)   | Substantial number of beneficiaries affected   | No           |
| May 05 updated for new drug Nov 06 | Topical Antifungals*                               | <ul style="list-style-type: none"> <li>▪ econazole</li> <li>▪ ciclopirox</li> <li>▪ oxiconazole (Oxistat)</li> <li>▪ sertaconazole (Ertaczo)</li> <li>▪ sulconazole (Exelderm)</li> </ul>   | 49,743  | 14,266                        | 33,430  | 2,047      | 17 Aug 05 (30 days)   | Medication used to treat acute (not chronic) infections not likely to require therapy change | No           |
|                                    |  | <ul style="list-style-type: none"> <li>▪ miconazole 0.25%, zinc oxide 15%, white petrolatum 82.35% (Vusion)</li> </ul>  | 581 (Apr 06-Oct 06) (UU not applicable)               | 7                             | 571     | 3          | 21 Feb 07 (60 days)   | Small numbers of beneficiaries affected  | No           |
| May 05                             | MS-DMDs  | -   | 0   | 0                             | 0       | 0          | Not applicable  | No medications moved to non-formulary status   | No           |



| Meeting | Drug Class | Non-Formulary Medications   | Total Beneficiaries Affected (# of patients affected) | Beneficiaries Affected by POS |         |            | Implementation Plan<br>First Wednesday X days after the decision date | Justification  | Step Therapy |
|---------|------------|---|---|-------------------------------|---------|------------|---|--|--------------|
|         |            |   |   | MTF                           | Retail  | Mail Order |   |  |              |
| Feb 05  | ARBs       | <ul style="list-style-type: none"> <li>▪ eprosartan (Teveten)</li> <li>▪ eprosartan/HCTZ (Teveten HCT)</li> </ul> | 2,184   | 13                            | 1,644   | 527        | 17 Jul 05<br>(90 days)  | Recommended 30-day implementation overturned; 90-day BAP recommendation accepted | No           |
| Feb 05  | PPIs       | <ul style="list-style-type: none"> <li>▪ esomeprazole (Nexium)</li> </ul>   | 138,739   | 6,691                         | 117,520 | 14,528     | 17 Jul 05<br>(90 days)  | Substantial number of beneficiaries affected                                     |              |

BCF = Basic Core Formulary; ECF = Extended Core Formulary; ESI = Express-Scripts, Inc; MN = Medical Necessity; TMOP = TRICARE Mail Order Pharmacy; TRRx = TRICARE Retail Pharmacy program; UF = Uniform Formulary

CR = controlled release; ER = extended release; IR = immediate release; LA = long-acting; SR = sustained release; XL = extended release

5-ARI = 5-Alpha Reductase Inhibitors; ADHD = Attention Deficit Hyperactivity Disorder; ACE Inhibitors = Angiotensin Converting Enzyme Inhibitors; ARBs = Angiotensin Receptor Blockers; BPH = Benign Prostatic Hypertrophy; CCBs = Calcium Channel Blockers; EE = ethinyl estradiol; GSAs = Growth Stimulating Agents; GI = gastrointestinal; GABA = gamma-aminobutyric acid; H2 = Histamine-2 receptor; HCTZ = hydrochlorothiazide; Leukotriene Modifiers = LMs; LIP-1s = Antilipidemic I; LIP-2s = Antilipidemic II; MAOI = Monoamine Oxidase Inhibitor; MS-DMDs = Multiple Sclerosis Disease-Modifying Drugs; NAs = Newer Antihistamines; OABs = Overactive Bladder Medications;

PDE-5 Inhibitors = Phosphodiesterase-5 inhibitors; PMDD = Premenstrual Dysmorphic Disorder; PPIs = Proton Pump Inhibitors; RAAs = Renin Antihypertensive Agents; SODAS = spheroidal oral drug absorption system; TZDs = thiazolidinediones

\*The topical antifungal drug class excludes vaginal products and products for onychomycosis (e.g., ciclopirox topical solution [Penlac])